| Prev Close | 81.92 |
| Open | 82.41 |
| Day Low/High | 81.60 / 82.96 |
| 52 Wk Low/High | 62.01 / 87.07 |
| Volume | 4.98M |
| Avg Volume | 10.91M |
Merck & Co. Inc. (MRK)
82.64
0.72
0.88
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 2.57B |
| Market Cap | 210.07B |
| EPS | 2.30 |
| P/E Ratio | 47.44 |
| Div & Yield | 2.20 (2.63%) |
Jim Cramer on Amazon, Tesla, Starbucks, Exxon, Chevron, American Airlines, Southwest Airlines, Merck and Tax Reform
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending stocks.
Does Merck's Rally Have Legs?
MRK has shaped up on the charts.
Cramer: Stop Talking About the 'Market'
It just isn't as useful or descriptive right now.
4 Undervalued Biotech Stocks
Two are turnaround stories, and two are oversold.
47 Quarterly Dividend Declared By Merck
Merck , said today that its board of directors authorized a quarterly dividend of 47 cents
Cramer: Let Loose the Growth Hounds
Day 2 of the selloff brings in an entirely new kind of buyer.
Closing Bell: Snap Sells Off After Weak Quarter; Macy's, Kohl's Sink Wall Street
Stocks hold losses as a selloff in Snap pulls the rest of the tech sector lower.
Merck Ready to Resume Long-Term Uptrend
The price momentum and money flow indicators of the drug maker are in positive alignment.
Blue-Chip Breakouts: Intel, Boeing, and Merck Are Ready to Spring Higher in May
These three big stocks are teetering on the edge of breakout territory to start the month.
The Good, the Bad and the Ugly (Late Afternoon Edition)
"It's not a joke, it's a rope, Tuco. Now I want you to get up there and put your head in that noose." -- Blondie, " The Good, the Bad and the Ugly" No "Takeaways" today as I have I might be trading some of the earnings reports that will be released ...
Wake Up Wall Street: Trump Considers Breaking Up Big Banks
Trump suggested he could split their consumer businesses from investment operations
2 'Swing for the Fences' Small Biotechs
Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.
2 'Swing for the Fences' Small Biotechs
Genocea Biosciences and Eiger Biopharmaceuticals are high risk/high reward plays.
Surveying the NASH Drug Landscape
Biotech investors should keep a close eye on the progress in this huge potential market.
Takeaways and Observations (Early Edition)
"Doug Kass wrote an article today about how he fears the lack of fear in this market. I agree with Doug that lack of fear is an issue, but it goes further than that. What this market has missed for quite some time is strong emotion. There may not be...
Jim Cramer Says Incyte Has an Amazing Pipeline of Treatments
'These companies are all assessing the Trump effect,' Cramer said.
Cramer: Stay the Course, but Keep Cash Handy
It's pretty normal to have profit-taking after such a strong first quarter.
Cramer: We Have Nothing to Distinguish the Stocks Right Now
We know that we are in the era when index managers are ascendant.
Cramer: 3 Health Care Bill Scenarios, 3 Game Plans
Get your plan in place, but understand that the Republic is not in jeopardy.
Today's Takeaways and Observations (Early Edition)
"I would describe today's market action as "benign." And that applies to almost every asset class." -- Kass Diary 104 trading sessions without a one percent drop in the indices. "Don't Think the Machines Could Turn to Selling? You've Forgotten 1987....
Health Care Putting in a Base
Healthcare stocks had a heckuva four-year period of over-performance that ended in the summer of 2015. Since then the Health Care Select Sector SPDR ETF (40% pharma and 15% biotech) has had a series of trading-range moves as sector prices lagged. La...
Cramer: When a Trump Tweet Is a Buy Signal
Drug companies are the latest targets/beneficiaries.
Drugmakers Suffer After Trump Tweet
Stocks were under pressure again after Donald Trump made vague promises to lower drug prices.
Cramer: Top 10 Bull Markets Right Now
Bull market number one, perhaps of all time: the financials.
What You Should Know About OncoSec's IL-12 Melanoma Immunotherapy
In a 24-week trial of 22 patients, OncoSec saw a 41% response rate
Cramer: This Drug Rally Is No Longer 'Trumped Up'
Let's recognize that some moves are simply related to bonds, which are in the grips of a bizarre developed-world shortage.
What Jim Cramer Expects From Valeant Pharmaceuticals' Results on Tuesday
TheStreet's Action Alerts PLUS Portfolio Manager Jim Cramer is keeping an eye on quarterly results from Valeant Pharmaceuticals on Tuesday.
Home Depot, Visa, Netflix Are Rocket Stocks to Watch
Without further ado, here's a look at this week's Rocket Stocks.
Cramer: I'll Give You the Key to the Rally
You have to keep up with the sector rotations.
Meet 4 Women Serving on the Boards of 4 Companies at the Same Time
Four women serve on the boards of four S&P 500 companies at the same time.
